Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
Advertisement

Related Content

Sanofi Looks To Build Stronger Alliances To Fuel R&D In Korea
Korea’s Health Ministry Selects 43 Innovative Companies For Tax/Funding Benefits
Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
South Korean Ministry of Health's Lee Hae-hee On Partnership With AstraZeneca To Bolster Domestic Firms' Global Aspirations: An Interview With PharmAsia News.
Korea And U.S. Health Ministers Agree To Enhance Cooperation In Anticipation Of Increased Pharma, Device Trade
Korea And U.S. Health Ministers Agree To Enhance Cooperation In Anticipation Of Increased Pharma, Device Trade
Revised U.S.-Korea FTA Grants Three-year Grace Period To Korean Generic Drug Makers
Deals With Pfizer, Sanofi-Aventis, AstraZeneca Boost Korea As Clinical Trial Destination
South Korea-U.S. Free Trade Agreement Likely To Put Stranglehold On Local Korean Drug Makers
Advertisement
UsernamePublicRestriction

Register

SC077819

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel